Al-Mufti Fawaz, Morris Nicholas, Lahiri Shouri, Roth William, Witsch Jens, Machado Iona, Agarwal Sachin, Park Soojin, Meyers Philip M, Connolly E Sander, Claassen Jan
Departments of Neurology, Columbia University Medical Center, New York, NY, USA.
Departments of Neurology, Columbia University Medical Center, New York, NY, USA; Department of Neurosurgery, Columbia University Medical Center, New York, NY, USA.
J Vasc Interv Neurol. 2016 Jun;9(1):28-34.
Intra-aortic counterpulsation balloon pumps (IABPs) have been widely used to augment hemodynamics in critically ill patients with cardiogenic shock and have recently been proposed as a management strategy for subarachnoid hemorrhage (SAH) patients with neurogenic stress cardiomyopathy (NSC). Prior case series have described the use of IABP as a means to manage cardiogenic shock in this patient population; however, we sought to describe our experience with IABP as a means to wean vasopressor requirement while augmenting hemodynamics and maintaining pressures at goal.
Five patients were identified from a single center, prospective, observational cohort study that received an IABP for the management of ischemia related to cerebral vasospasm in the setting of NSC. We evaluated all cases for efficacy of IABP in reducing vasopressor requirement, and complications.
Vasopressor requirements were reduced by a mean of 50% (range 25-65%) following IABPs placement within 24-48 h. There were no significant complications from IABPs. Out of the five patients, the outcome in three cases was favorable (mRS≤1). Two patients suffered delayed cerebral ischemia (DCI), one patient passed away due to severe sepsis, and one patient was left with severe disability. Only one patient required anticoagulation and that was for a preexisting deep venous thrombosis.
The use of IABPs may be beneficial as an adjunctive therapy in SAH patients with concomitant symptomatic vasospasm and NSC.
主动脉内反搏球囊泵(IABP)已被广泛用于增强心源性休克重症患者的血流动力学,最近有人提出将其作为蛛网膜下腔出血(SAH)合并神经源性应激性心肌病(NSC)患者的一种治疗策略。先前的病例系列描述了在这一患者群体中使用IABP来治疗心源性休克;然而,我们试图描述我们使用IABP作为一种手段来减少血管升压药需求,同时增强血流动力学并将血压维持在目标水平的经验。
从一项单中心、前瞻性、观察性队列研究中确定了5例患者,这些患者因NSC合并脑血管痉挛相关的缺血管理而接受了IABP治疗。我们评估了所有病例中IABP在降低血管升压药需求方面的疗效以及并发症情况。
在24 - 48小时内放置IABP后,血管升压药需求平均降低了50%(范围为25% - 65%)。IABP未出现显著并发症。5例患者中,3例预后良好(改良Rankin量表评分≤1分)。2例患者发生迟发性脑缺血(DCI),1例患者因严重脓毒症死亡,1例患者遗留严重残疾。只有1例患者需要抗凝治疗,原因是其存在既往深静脉血栓形成。
对于伴有症状性血管痉挛和NSC的SAH患者,使用IABP作为辅助治疗可能有益。